Vaxcyte Inc. (PCVX)
Vaxcyte Inc. (PCVX) Stock Price, Analysis & Data
| Bid | 43.34 |
| Market Cap | 8.9B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.06B |
| Beta | 1.21 |
| EPS (ttm) | -7.63 |
| PE Ratio (ttm) | n/a |
| Forward PE | -8.29 |
| P/B (ttm) | 3.14 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 3, 2026 |
| Ask | 76.4 |
| Volume | 546,883 |
| Avg. Volume (20D) | 1,454,625 |
| Open | 58.74 |
| Previous Close | 59.22 |
| Day's Range | 58.74 - 60.41 |
| 52-Week Range | 29.87 - 65.00 |
| Analyst | Strong Buy |
| Price Target | 110 (83.88%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PCVX
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of...
Financial Performance
In 2025, Vaxcyte's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -766.63M, an increase of 65.25%.
Financial StatementsAnalyst Forecast
According to 9 analyst ratings, the average rating for PCVX stock is "Strong Buy". The 12-month stock price forecast is 110, which is upside of 83.88% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
